Wee-1 kinase patent approval granted

Wee-1 kinase patent approval granted

May 8, 2017

Almac Discovery Announces key Wee-1 kinase patent approval

Inhibitors of Wee-1 kinase, cell cycle regulator, have potential for clinical utility across a broad range of cancer indications

Craigavon, N.I., UK, 08 May 2017 Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, today announced that the United States Patent and Trademarks office (USPTO) has granted patent protection for a key patent family for its Wee-1 kinase inhibitor program.

The team of experts at Almac Discovery, headquartered in Belfast, Northern Ireland, designed and optimized the novel Wee-1 kinase inhibitors which exhibit high potency and excellent selectivity. The inhibitors demonstrate potent anti-proliferative activity, both in vitro and in vivo, and in combination with genotoxics and as a single agent.

Many cancer treatments such as radiation, antimetabolites, alkylating agents, DNA topoisomerase inhibitors and platinum compounds damage DNA in cells. The cellular response is to arrest the cell cycle temporarily to allow for DNA repair hence reducing the effects of chemotherapy. The Wee-1 kinase appears to be a key regulator of a number of cell cycle checkpoints. These findings mean that Wee-1 kinase inhibitors may have great value across a multitude of cancer types in both combination and monotherapy modalities.

Dr Stephen Barr, Managing Director & President, Almac Discovery commented “We are delighted to have received notification of patent approval for our Wee-1 inhibitor program for the US marketplace.  This allowance expands our pipeline of best-in-class oncology projects and reaffirms Almac Discovery’s position as a partner of choice in the challenging world of modern drug discovery.”

About Almac Discovery

Almac Discovery is a research driven oncology company dedicated to the discovery and development of novel and innovative approaches to the treatment of cancer. Almac Discovery focuses on the discovery to preclinical stage seeking to partner programs at an early time point with the pharmaceutical industry. Exceptionally the company will undertake clinical development to an early stage before partnering. Almac Discovery is part of the Almac Group.

For more information, please visit www.almacgroup.com/discovery or e-mail media@almacgroup.com.

About Almac Group
‘Partnering to Advance Human Health’

The Almac Group is an established contract development and manufacturing organization that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery development and commercialization, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organization that has organically grown almost 50 years and now employs in 5,000 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations in the UK, Ireland, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).

 

Share

Back to news